Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9636407 | FRESENIUS KABI USA | Caspofungin acetate formulations |
Dec, 2032
(9 years from now) |
Market Authorisation Date: 30 December, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
6
United States
1
Portugal
1
Hungary
1
Slovenia
1
Croatia
1
Hong Kong
1
San Marino
1
Poland
1
Denmark
1
Lithuania
1
Spain
1
Canada
1
Cyprus
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic